Oncology Now

Live Webcasts with the latest updates from the Annual Oncology Meeting

Comprehensive therapeutic areas covered at convenient dates and times

Exploring Future Applications of HER2/3-Targeted Therapies Across Multiple Tumor Types

Associate Professor of Medicine, Division of Hematology/Oncology
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Director, Breast Cancer Clinical 

Trials Program
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
David Geffen School of Medicine at UCLA
Santa Monica, CA


Sara A. Hurvitz, MD

Live Webcast | Earn 2.0 CME Credits 

May 30, 2020 7:30 - 9:30 PM ET

Agenda Highlights:
  • Therapeutic Targeting of the HER2/3 Pathway 
    in Cancer
  • The Impact of HER2-Targeted Strategies on the Treatment of Breast Cancer
  • A Look at the Role of HER2/3 in Gastrointestinal Malignancies
  • Targeting HER2/3 in Lung Cancer

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Benefits of Attending:
  • Gain awareness of the clinical trials evaluating current and emerging HER2/3-targeted therapies for treatment of breast, lung, and gastrointestinal cancers that may affect your practice 
    in the future
  • Understand optimal HER2 testing methods for different tumor types
  • Learn how the experts and your peers are managing challenging cases across multiple HER2-positive cancer types
  • Ask the experts about best practices for mitigating adverse events related to HER2/3-targeted therapies

The Latest Advances on NEDD8 Inhibition for Treatment of Higher-Risk MDS and Other Hematologic Malignancies

Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia, Division of 

Cancer Medicine
The University of Texas MD Anderson 

Cancer Center
Houston, TX

Guillermo Garcia-Manero, MD

June 25, 2020 8:00 - 10:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Agenda Highlights:
  • The Evolving Role of NEDD8 Across Hematologic Cancers
  • Diagnosis and Risk Stratification of Myelodysplastic Syndrome (MDS)
  • Exploring the Evolving Impact of NEDD8 Inhibitors in Higher-Risk MDS
  • Evolving NEDD8 Inhibitors for the Management of Other Hematologic Malignancies – A Focus on Chronic Myelomonocytic Leukemia (CMML)
  • Evolving NEDD8 Inhibitors for the Management of Other Hematologic Malignancies – A Focus on Acute Myeloid Leukemia (AML)
  • Case Discussion: Patient Diagnosed With High-Risk MDS

This activity is supported by an educational grant from Takeda Oncology.

Benefits of Attending:
  • Outline the mechanism of action of the NEDD8 pathway and its evolving role in 
    hematologic malignancies
  • Explain the role of emerging NEDD8 inhibitors for the treatment of high-risk MDS and other hematologic malignancies
  • Consider patients who may be eligible for NEDD8 inhibitor treatment
  • Assess adverse events and management strategies associated with NEDD8 inhibitor treatment

Medical Crossfire®: Novel Applications of Liquid Biopsies Across Cancer Care


Benjamin P. Levy, MD

June 17, 2020 8:00 - 10:00 PM EDT

Live Webcast | Earn 2.0 CME Credits

Associate Professor of Oncology, Johns Hopkins University School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
Agenda Highlights:
  • Liquid Biopsy: Novel Applications Across Lung Cancer Care
  • Focus on Breast Cancer and the Emerging Role of Plasma Tests
  • Focus on the Role of Liquid Biopsies in Gastrointestinal Cancers

This educational activity is supported by educational grants from AstraZeneca; Foundation Medicine, Inc.; GRAIL; Guardant Health, Inc.; and Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Benefits of Attending:
  • Summarize the comparative advantages of currently available liquid-based and tissue-based testing approaches
  • Evaluate clinical data concerning new and emerging liquid biopsy technologies
  • Describe emerging uses of liquid biopsies across the spectrum of cancer care, including in NSCLC, breast cancer, and GI cancers
  • Assess clinical evidence pertaining to specific testing modalities that may help to individualize treatment protocols for patients with cancer

Hepatocellular Carcinoma Tumor Board: The Experts Address Novel Regimens and Emerging Sequencing Considerations


R. Kate (Katie) Kelley, MD

June 25, 2020 2:00 - 4:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Re-airing: June 26, 2020 5:00 - 7:00 PM ET

Associate Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology), UCSF
San Francisco, CA
Agenda Highlights:
  • How HCC Biology and Biomarkers Have Informed Rational Drug Development
  • Tumor Board 1: What Informs Treatment Selection for Newly Diagnosed HCC
  • Tumor Board 2: Integrating Evolving Treatment Options in First-Line Therapy for Metastatic HCC
  • Tumor Board 3: How Will We Optimize Treatment Strategies in the Second-Line Setting and Beyond?

This educational activity is supported by educational grants from AstraZeneca; Genentech, Inc.; and Merck & Co., Inc.

Benefits of Attending:
  • Learn from the experts about how they handle challenging clinical cases using multidisciplinary teams and how they optimize sequencing of therapies in HCC
  • Improve your knowledge about HCC biology and biomarkers in the context of how they have informed rational drug development
  • Learn about the latest clinical trial data regarding the safety and efficacy of current and emerging agents for the treatment of HCC
  • Gain expert perspectives on best practices for mitigating adverse events related to novel therapies for HCC

Expert Perspectives in Relapsed/Refractory DLBCL: A Look to the Future of Care


Grzegorz S. Nowakowski, MD

June 5, 2020 8:00 - 10:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Hematology Specialist
Associate Professor
Mayo Clinic
Rochester, MN
Agenda Highlights:
  • Risk Assessment, Biomarkers, and Frontline DLBCL Therapy in 2020
  • Unmet Needs in Relapsed/Refractory DLBCL
  • Recent Data Sets in Relapsed/Refractory Transplant-Ineligible DLBCL
  • A Look to the Future: What Data May Emerge Next at EHA or ASH?

This educational activity is supported by an educational grant from MorphoSys US Inc.

Benefits of Attending:
  • Describe contemporary treatment strategies in multiple lines of DLBCL care and unmet clinical needs in DLBCL management
  • Examine testing approaches to stratify risk and monitor treatment responses among patients with DLBCL
  • Evaluate recent efficacy and safety findings from trials that evaluated novel approaches for patients with relapsed/refractory DLBCL
  • Explain how recent clinical trial evidence in relapsed/refractory DLBCL can be placed in the context of unmet needs in the field and late-stage ongoing studies in multiple lines of 
    DLBCL care

Integrating the Evidence to Optimize Treatment for Patients With Advanced RCC: An Expert Tumor Board Discussion


Toni K. Choueiri, MD

June 15, 2020 8:00 - 10:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Director, The Lank Center for 
Genitourinary Oncology
Dana-Farber Cancer Institute
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
The Jerome and Nancy Kohlberg Chair and Professor of Medicine
Harvard Medical School
Boston, MA
Agenda Highlights:
  • An Overview of Advanced RCC in 2020: Where are we now and Where are We Going?
  • What Forthcoming Data has to Potential to Impact Standards of Care?
  • Case 1: Patient with Newly-Diagnosed Metastatic RCC with Favorable-Risk Status
  • Case 2: Treatment Selection and Sequencing for a Patient with Poor/Intermediate Risk, 
    Metastatic RCC
  • Case 3: Treatment Strategies for a Patient with Good-Risk Metastatic RCC at Presentation, with Rapid Metastatic Progression Involving the Bone: Second-Line Therapy and Beyond
  • Case 4: Standards of Care and Investigational Strategies for Non-Clear Cell RCC

This educational activity is supported by educational grants from Eisai, Inc., Exelixis, Inc., and Merck & Co., Inc.

Benefits of Attending:
  • Review the pathobiology of RCC, and the therapeutic rationales for using targeted therapies and immunotherapies, both as single agents and in combination regimens.
  • Assess new and practice-changing data from clinical trials evaluating systemic agents such as targeted therapies and immunotherapies across multiple lines of therapy for 
    advanced/metastatic RCC.
  • Outline strategies to monitor and mitigate adverse events associated with targeted agents and immunotherapies used in the treatment of advanced/metastatic RCC.
  • Consider the efficacy and safety of systemic therapies, as well as biomarkers, disease characteristics, comorbidities, and patient preferences, in order to individualize and optimize treatment for patients with advanced/metastatic RCC.

Medical Crossfire®: How Can We Maximize Immuno-Oncology Strategies in Small Cell Lung Cancers?


Roy Herbst, MD, PhD

June 19, 2020 8:00 - 10:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
Agenda Highlights:
  • Biologic and Clinical Rationale for Immunotherapy in SCLC
  • Immunotherapy in Newly Diagnosed ES-SCLC: Definitive Advances in the Standard of Care
  • The Role of Immunotherapy in Subsequent Lines of Therapy in SCLC
  • Medical Crossfire®: Practical Issues and Future Prospects for Immunotherapy in SCLC

This activity is supported by an educational grant from AstraZeneca.

Benefits of Attending:
  • Hear expert perspectives on the best strategies for combining immunotherapy with chemotherapy for the treatment of 
    SCLC patients
  • Integrate results from the latest clinical studies into your practice decision-making
  • Evaluate safety considerations of immunotherapy in SCLC
  • Outline the latest strategies for the use of immunotherapy in patients with newly diagnosed and previously treated SCLC

Medical Crossfire®: Emerging Applications to Optimize and Individualize AML Treatment


Gail J. Roboz, MD

June 26, 2020 8:00 - 10:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York-Presbyterian Hospital
New York, NY
Agenda Highlights:
  • Setting the Stage for Treatment Decisions: Assessing Clinical Characteristics 
    and Biomarkers
  • Examining Frontline Options for Patients With AML Unfit for Intensive Induction Therapy
  • Medical Crossfire®: Evidence-Driven Frontline Treatment Selection for Elderly/Medically 
    Unfit Patients
  • Examining Induction Strategies for Medically Fit Patients with Newly-Diagnosed AML.
  • Medical Crossfire®: Evidence-Driven Selection of Induction Therapy for Younger/Fit Patients
  • Examining the Options for Patients With Relapsed/Refractory AML: Current and Emerging Treatment Options
  • On the Horizon: New Approaches Under Investigation for the Treatment of AML

This activity is supported by educational grants from AbbVie and Agios Pharmaceuticals, Inc.

Benefits of Attending:
  • Apply insights from leading experts to clinical cases to optimally use targeted therapy for patients with AML
  • Implement strategies to manage AML with current and emerging agents and best practices in supportive care
  • Recognize practical caveats to planning treatment regimens for difficult cases, such as those of older adults with AML
  • Implement increased knowledge of treatment options for relapsed/refractory AML into daily clinical practice

Exploring Current and Emerging Data Sets to Move Treatment of Ovarian Cancer Forward: A Focus on PARP Inhibition, Immunotherapy, and Beyond!


Ursula A. Matulonis, MD

July 1, 2020 8:00 - 10:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Director and Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Agenda Highlights:

  • Integration of PARP Inhibitors in the Continuum of Ovarian Cancer Treatment and Management: Where, When, and Who 
  • PARP Inhibitor Therapy After Multiple Lines of Chemotherapy
  • Matching PARP to Patient: Individualizing Care for Optimal Outcomes
  • PARP Inhibitor Therapy in the Maintenance Setting
  • The Evolving PARP Inhibitor Landscape: Expanding the Application of Novel Agents in Ovarian Cancer
  • Considerations for Clinical Trial Referral

This activity is supported by an educational grant from GlaxoSmithKline.

Benefits of Attending:

  • Interact with expert thought leaders in ovarian cancer
  • Analyze data from recent clinical trials in ovarian cancer and how these data may affect clinical practice
  • Identify potential opportunities to incorporate emerging treatments into the management of ovarian cancer
  • Optimize management strategies for patients with ovarian cancer

Medical Crossfire®: Impact of COVID-19 on Neutropenia Management in Cancer Care and the Advent of Novel Treatment Approaches


Douglas W. Blayney, MD

June 30, 2020 8:00 - 10:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Professor of Medicine, Oncology
Breast specialist
Stanford University Medical Center
Stanford, CA

Agenda Highlights:

  • Changing the Course of Neutropenia Management in Cancer Care
  • Reiterating the Gaps in Neutropenia Care: Addressing Key Concerns to Optimize Outcomes
  • Where We Will Be: Breakthrough Approaches to Treat and Manage Neutropenia in Cancer Care
  • Practical Methods to Optimize Outcomes With Neutropenia Prophylaxis and Management

This activity is supported by an educational grant from BeyondSpring Pharmaceuticals, Inc.

Benefits of Attending:

  • Learn about emerging treatments for neutropenia
  • Incorporate the latest clinical data for neutropenia into your practice
  • Hear how experts are managing patient care during the COVID-19 health crisis

Providing Patient-Centric Care in Pancreatic Cancer: Therapeutic Sequencing, Chemotherapy, and Novel Agents


Shubham Pant, MD

July 14, 2020 8:00 - 9:30 PM ET

Live Webcast | Earn 1.5 CME Credits

Associate Professor, Departments of Investigational Cancer
Therapeutics and Gastrointestinal Medical Oncology
Associate Director, Department of Sheihk Ahmed Center for
Early Phase Drug Development of Pancreatic Cancer Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Agenda Highlights:

  • Treatment Sequencing in Pancreatic Cancer
  • A New Focus on Maintenance Therapy in Pancreatic Cancer
  • Novel Therapies and Clinical Trials
  • Managing Borderline Resectable Pancreatic Cancer

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Benefits of Attending:

  • Learn about the most recent clinical advances for patients with pancreatic cancer
  • Hear experts discuss emerging data in the context of treatment decision making for patients with pancreatic cancer
  • Integrate emerging and investigational therapies into treatment planning for patients with pancreatic cancer
  • Incorporate strategies to effectively identify and manage adverse events that may occur with treatments for pancreatic cancer

Optimizing Outcomes in Prostate Cancer: Matching Treatment to Patient in the Modern Era


Philip Kantoff, MD 

July 14, 2020 10:00 AM - 12:00 PM ET

Live Webcast | Earn 2.0 CME Credits

Chairman of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical School
George J. Bosl Professor of Medicine
New York, NY 

Agenda Highlights:

  • The Evolving Landscape in the Management of High-Risk, Non-Metastatic CRPC
  • Applying the Evidence: Tumor Board Case Discussion of Non-Metastatic CRPC
  • State-of-the-Art Management of Metastatic CRPC 
  • Applying the Evidence: Tumor Board Case Discussion of Metastatic CRPC 

This activity is supported by educational grants from Exelixis and Sanofi Genzyme.

Benefits of Attending:

  • Hear the latest data applicable to treating patients with advanced and metastatic prostate cancer.
  • Learn how to use emerging data in challenging clinical scenarios for patients with castrate-resistant prostate cancer.
  • Interact with the expert panel and ask questions about treating patients with prostate cancer.